ArticleTherapeutic advances in musculoskeletal disease2026
Forced vital capacity as a survival predictor in systemic sclerosis-associated pulmonary hypertension.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary hypertension associated with systemic sclerosis (SSc-PH) carries a significant risk of mortality. Although interstitial lung disease (ILD) often coexists with SSc-PH, its impact on prognosis varies considerably depending on disease extension. The prognostic implications of different degrees of functional impairment secondary to ILD in patients with SSc-PH remain poorly understood. Objectives: This study aimed to stratify patients with SSc-PH according to their functional parameters and to identify potential prognostic factors in different patterns of ILD extension. Design: A retrospective study was conducted on consecutive patients with SSc-PH diagnosed according to the European Society of Cardiology/European Respiratory Society guidelines for PH since 2015, from two Italian Scleroderma Centers. Methods: Patients were classified according to high-resolution computed tomography (HRCT) findings and forced vital capacity (FVC) values as pulmonary arterial hypertension (PAH) without ILD, PH-ILD with FVC ⩾70%, or FVC <70%. Survival analysis, clinical outcomes, and prognostic factors were assessed by Kaplan-Meier curves, multivariate logistic regression, and receiver operating characteristic (ROC) analysis. Results: Fifty-three patients with SSc-PH were enrolled, and their 5-year overall survival rate was 66.7%. The 29 patients with PH-ILD demonstrated significantly lower survival than the 24 patients with PAH (48% vs 87%, Conclusion: An FVC <70% at baseline represents an important negative prognostic factor in patients with SSc-PH, independently of the extension of ILD on HRCT scan. Functional assessment may complement radiological evaluation and emphasize the importance of routine monitoring of lung function for risk stratification in patients with SSc-PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.